InvestorsHub Logo
Followers 230
Posts 21488
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Friday, 01/20/2023 6:23:52 AM

Friday, January 20, 2023 6:23:52 AM

Post# of 2847
Excerpt : "We have evaluated the drug levels and cytokine responses in the SB102 study," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "The PK and PD from 3 cohorts have been formally simulated to predict the levels of the most responsive cytokines. Interferon gamma (IFNg) levels rose after SON-1010 dosing as expected, but with lower peak elevations and much longer decay than those observed historically for rhIL-12, which correlates with better tumor control in preclinical models. Linking IL-12 to the FHAB is designed to permit use of higher doses of this cytokine without triggering unacceptable toxicity, allowing us to safely induce a successful local immune response to IL-12 in the TME."


https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-pharmacokinetic-pharmacodynamic-130000814.html
Bullish
Bullish


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SONN News